NCT01204580View on ClinicalTrials.gov

ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GLIMEPIRIDE + METFORMIN

Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Jakarta

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01204580 - ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination | Biotech Hunter | Biotech Hunter